FDA Clearance Tracker · P110033-S070
Juvéderm® Voluma® XC
Last checked: Nov 20, 2026Latest source record: Oct 6, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Oct 6, 2023
Approved
Time to decision
177 days
Received Apr 12, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
Device type
- Device type
- Implant, dermal, for aesthetic use (LMH)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for Juvéderm Voluma XC for supraperiosteal injection to augment the temple region to improve moderate to severe temple hollowing in adults over the age of 21.
Source documents
Other decisions for Allergan
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SKINVIVE by JUVEDERM®PMA supplement
P110033-S099 · Decided Jun 11, 2026 · 394 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.